{"data":{"responsecode":"000","responsemsg":"","quote":{"hi":"64.500","rs_stock_flag":false,"fiscal_year_end":"31 Dec 2025","hist_closedate":"25 Sep 2025","replication_method":null,"amt_os":"153,278,691","primaryexch":"HKEX","ric":"9887.HK","product_subtype":null,"db_updatetime":"26 Sep 2025 18:38","mkt_cap_u":"B","am_u":"M","ew_sub_right":"","secondary_listing":false,"ew_amt_os_cur":null,"ccy":"HKD","management_fee":"","ew_underlying_code":null,"trdstatus":"N","nav":"","original_offer_price":"","issue":"","asset_class":null,"eps":null,"inline_upper_strike_price":"","sedol":"BQTYGN9","am":"19.30","iv":"","ew_strike":"","as":"62.950","geographic_focus":null,"incorpin":"PRC","etp_baseCur":null,"ew_amt_os":"","bd":"62.400","registrar":"Computershare Hong Kong Investor Services Ltd.","depositary":null,"exotic_type":null,"callput_indicator":null,"primary_market":null,"underlying_index":null,"lot":"100","update_time":"2025-09-26 10:38:37.0","lo52":"57.450","shares_issued_date":"31 Aug 2025","premium":"","strike_price_ccy":null,"yield":"","vo_u":"K","base_currency":null,"coupon":"","expiry_date":"","chairman":"Kang Xiaoqiang","underlying_ric":"9887.HK","hi52":"83.600","issuer_name":"Nanjing Leads Biolabs Co., Ltd. - B - H Shares","h_share_flag":false,"ew_sub_per_from":"","div_yield":"","interest_payment_date":"-","updatetime":"26 Sep 2025 16:08","aum_date":"","lo":"62.050","mkt_cap":"9.64","f_aum_hkd":null,"ew_sub_per_to":"","ls":"62.900","nav_date":"","csic_classification":null,"floating_flag":false,"issued_shares_note":null,"nom_ccy":null,"eff_gear":"","board_lot_nominal":null,"hsic_ind_classification":"Healthcare - Pharmaceuticals & Biotechnology","ew_desc":null,"inception_date":"","nc":"-1.200","aum":"","issued_shares_class_B":null,"vo":"306.03","secondary_listing_flag":false,"listing_date":"25 Jul 2025","issued_shares_class_A":null,"as_at_label":"as at","ew_amt_os_dat":"","nm":"Nanjing Leads Biolabs Co., Ltd. - B - H Shares","nm_s":"LEADS BIOLABS-B","sym":"9887","inline_lower_strike_price":"","listing_category":"Primary Listing","ew_strike_cur":null,"exotic_warrant_indicator":null,"investment_focus":null,"call_price":"","tck":"0.050","strike_price":"","summary":"Nanjing Leads Biolabs Co Ltd is a China-based company primarily engaged in the discovery, development, and commercialization of new therapies in oncology, autoimmune, and other severe diseases. The Companyâ€™s main drug candidates include LBL-024, LBL-034, LBL-033, LBL-007 and others. The company's LBL-024 is mainly used to treat extra-pulmonary neuroendocrine carcinoma (EP-NEC), small cell lung cancer (SCLC), biliary tract carcinoma (BTC), non-small-cell lung cancer (NSCLC), esophageal squamous cell carcinoma (ESCC), hepatocellular carcinoma (HCC), gastric cancer (GC) and other solid tumors. The Company has also developed multiple proprietary technology platforms, including LeadsBod platform (a CD3 T-cell engager platform), X-body platform (a 4-1BB engager platform) and several other bispecific antibody and fusion protein platforms. The Company mainly conducts its business in the domestic market.","op":"62.050","aum_u":"","nav_ccy":null,"class_B_description":null,"os":"","wnt_gear":"","transfer_of_listing_date":"","hsic_sub_sector_classification":"Biotechnology","amt_ccy":null,"class_A_description":null,"domicile_country":null,"entitlement_ratio":"","product_type":"EQTY","office_address":"Building 05, Accelerator IV<br/>No. 122 Huakang Road<br/>Jiangbei New District<br/>Nanjing, Jiangsu Province, PRC","pc":"-1.87","days_to_expiry":null,"underlying_code":null,"pe":"","eps_ccy":null,"hdr":false,"launch_date":"","hc":"64.100","isin":"CNE1000070H8","moneyness":""}},"qid":"1758890327645"}
